Gemcitabine activates the Hippo signaling pathway and suppresses tumor growth by stabilizing large tumor suppressor kinase 2 through the hypoxia‐inducible factor 1‐alpha/ubiquitin protein ligase E3 component N‐recognin 5 axis
Jin Zhang, Lixia Xu, Kai Guo, Weijia Dong, Xin Dai, Donghua Gu · 2026
Read Gemcitabine activates the Hippo signaling pathway and suppresses tumor growth by stabilizing large tumor suppressor kinase 2 through the hypoxia‐inducible factor 1‐alpha/ubiquitin protein ligase E3 component N‐recognin 5 axis by Jin Zhang, Lixia Xu, Kai Guo, Weijia Dong, Xin Dai, Donghua Gu (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13274678.txt.
Description
Jin Zhang and co-authors report a 2026 journal article uncovering an extra way the chemotherapy drug gemcitabine fights ovarian cancer. Beyond its known DNA damage, the drug's full mechanism was unclear. The team traced a chain involving HIF1A, a low-oxygen sensor, and UBR5, a protein that tags other proteins for disposal.
In ovarian cancer, HIF1A switches UBR5 on, and UBR5 destroys LATS2, a brake protein in the Hippo growth-control pathway. Gemcitabine lowered HIF1A and UBR5, sparing LATS2 and switching the Hippo brake back on, which quieted two growth signals, YAP1 and FGFR1. Treated cancer cells grew, moved, and invaded less, and tumors shrank in an orthotopic mouse model.
Catalog record
| CREATOR | Jin Zhang, Lixia Xu, Kai Guo, Weijia Dong, Xin Dai, Donghua Gu |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 72281 |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |